… transplant recipients with CMV disease, oral valganciclovir has comparable safety and is not
inferior to standard iv ganciclovir treatment … the management of CMV disease, for patients, …

… or treatment with once-daily oral dosing in transplant recipients. Following organ transplantation,
a majority of allograft recipients … CMV disease in liver transplant recipients ranges from …

… transplant recipients treated with valganciclovir 900 mg once daily or oral ganciclovir 1000
mg three times daily. Dosage was adjusted according to estimated creatinine clearance …

… outcomes in transplant patients treated with oral valganciclovir or … oral valganciclovir for
treatment of CMV disease in SOT recipients… CMV disease in treated patients. Recurrence rates in …

… trial in transplant patients, valganciclovir was as clinically effective as oral ganciclovir with a
comparable safety profile and the absence of ganciclovir resistance. Valganciclovir was also …

… There was no need to change valganciclovir treatment for any of our patients as a result of …
related to the patients treated with valganciclovir. Moreover, there were few patients with tissue…

… to intravenous GCV in the treatment of CMV infection and … treatment with VGC of heart and
lung transplant recipients with … in treatment of CMV disease in 21 renal transplant recipients …

… oral valganciclovir treatment as the standard treatment option… , such as pediatrics and patients
with questionable oral drug … concentrations with oral valganciclovir treatment. Regarding …

… in the number of patients with tissue-invasive CMV in the Valcyte arm vs the ganciclovir arm
(… , Valcyte was not approved for the prevention of CMV disease in liver transplant recipients.” …

… We decided to use the 450‐mg dose in our patients because kidney transplant recipients …
Half of our valganciclovir‐treated patients required the MMF and/or valganciclovir doses to be …